FBLN2 promoter hypermethylation: a negative prognostic biomarker and anti-PD-1 response predictor in clear cell renal cell carcinoma via high-throughput CpG Island screening.
1/5 보강
[BACKGROUND] Clear cell renal cell carcinoma (ccRCC), with rising incidence globally, shows heterogeneous responses to immune checkpoint blockade (ICB).
- 표본수 (n) 335
- p-value P < 0.001
- p-value P = 0.023
- HR 3.45
APA
Liao W, Yu L, et al. (2025). FBLN2 promoter hypermethylation: a negative prognostic biomarker and anti-PD-1 response predictor in clear cell renal cell carcinoma via high-throughput CpG Island screening.. Clinical epigenetics, 17(1), 169. https://doi.org/10.1186/s13148-025-01981-2
MLA
Liao W, et al.. "FBLN2 promoter hypermethylation: a negative prognostic biomarker and anti-PD-1 response predictor in clear cell renal cell carcinoma via high-throughput CpG Island screening.." Clinical epigenetics, vol. 17, no. 1, 2025, pp. 169.
PMID
41063327 ↗
Abstract 한글 요약
[BACKGROUND] Clear cell renal cell carcinoma (ccRCC), with rising incidence globally, shows heterogeneous responses to immune checkpoint blockade (ICB). DNA methylation dysregulation impacts tumor immunity, necessitating predictive CpG methylation biomarkers for ICB efficacy.
[METHODS] Genome-wide methylation profiling (TCGA/GEO) identified prognostic promoter CpG islands linked to CD8⁺ T cell infiltration. Single-CpG resolution analysis guided TaqMan probe design, validated in two independent cohorts: non-ICB (n = 335) for prognosis and ICB-treated (n = 45) for immunotherapy prediction.
[RESULTS] High-throughput methylation analysis identified hypermethylation at the FBLN2 promoter (chr3:13590414-13591008), which correlated with advanced tumor stage, higher grade, and poorer overall survival (OS) and progression-free survival (PFS). This locus exhibited significant associations with CD8⁺ T cell infiltration and IFNγ pathway activation. In the non-ICB cohort, validation using a 5-CpG TaqMan assay confirmed FBLN2 hypermethylation as an independent prognostic marker for both OS (HR = 3.45, P < 0.001) and PFS (HR = 2.43, P = 0.023). Subsequent IHC analysis of 74 tumor specimens demonstrated strong concordance between FBLN2 percent methylation ratio (PMR) and CD8⁺ T cell density (r = 0.62, P < 0.0001). In the anti-PD-1-treated cohort, high FBLN2 methylation was associated with a favorable immunotherapy response (Cohen's weighted Kappa = 0.607, P < 0.001) and predicted superior PFS (median 11.2 vs 3.4 months, HR = 0.35, P = 0.006), suggesting its potential as a novel predictive biomarker for ICB efficacy.
[CONCLUSIONS] FBLN2 promoter hypermethylation is a promising prognostic biomarker in ccRCC and a potential predictor of immunotherapy response. These findings warrant further investigation to validate its potential for enhancing personalized patient management.
[METHODS] Genome-wide methylation profiling (TCGA/GEO) identified prognostic promoter CpG islands linked to CD8⁺ T cell infiltration. Single-CpG resolution analysis guided TaqMan probe design, validated in two independent cohorts: non-ICB (n = 335) for prognosis and ICB-treated (n = 45) for immunotherapy prediction.
[RESULTS] High-throughput methylation analysis identified hypermethylation at the FBLN2 promoter (chr3:13590414-13591008), which correlated with advanced tumor stage, higher grade, and poorer overall survival (OS) and progression-free survival (PFS). This locus exhibited significant associations with CD8⁺ T cell infiltration and IFNγ pathway activation. In the non-ICB cohort, validation using a 5-CpG TaqMan assay confirmed FBLN2 hypermethylation as an independent prognostic marker for both OS (HR = 3.45, P < 0.001) and PFS (HR = 2.43, P = 0.023). Subsequent IHC analysis of 74 tumor specimens demonstrated strong concordance between FBLN2 percent methylation ratio (PMR) and CD8⁺ T cell density (r = 0.62, P < 0.0001). In the anti-PD-1-treated cohort, high FBLN2 methylation was associated with a favorable immunotherapy response (Cohen's weighted Kappa = 0.607, P < 0.001) and predicted superior PFS (median 11.2 vs 3.4 months, HR = 0.35, P = 0.006), suggesting its potential as a novel predictive biomarker for ICB efficacy.
[CONCLUSIONS] FBLN2 promoter hypermethylation is a promising prognostic biomarker in ccRCC and a potential predictor of immunotherapy response. These findings warrant further investigation to validate its potential for enhancing personalized patient management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Renal Cell
- DNA Methylation
- Promoter Regions
- Genetic
- Kidney Neoplasms
- CpG Islands
- Prognosis
- Female
- Male
- Biomarkers
- Tumor
- Middle Aged
- Immune Checkpoint Inhibitors
- Aged
- High-Throughput Screening Assays
- Programmed Cell Death 1 Receptor
- CD8-Positive T-Lymphocytes
- FBLN2
- Clear cell renal cell carcinoma
- CpG Island
- Immunotherapy response predictor
- Methylation
같은 제1저자의 인용 많은 논문 (4)
- Lung Cancer Diagnosis Rates in Early Detection Programs in the Mississippi Delta.
- Signature Construction Associated with Tumor-Infiltrating Macrophages Identifies IRF8 as a Novel Biomarker for Immunotherapy in Advanced Gastric Cancer.
- Synergistic inhibition of hepatocarcinogenesis by green alga Ulva lactuca polysaccharide and 5-fluorouracil targeted SERPINH1.
- Natural products based on Correa's cascade for the treatment of gastric cancer trilogy: Current status and future perspective.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.